Metastatic non‐small cell lung cancer estimated overall survival by year of diagnosis, 2015 versus 1990. When the proportion of patients receiving systemic therapy in 2015 was increased by 10% (Scenario 1) or 30% (Scenario 2), the improvement in survival relative to 1990 increased by 5.1 months (39,700 population life years) and 6.9 months (53,800 population life years), respectively.
Abbreviations: NSCLC, non‐small cell lung cancer.